Skip to main content
. 2019 Sep 2;14(14):1235–1242. doi: 10.2217/fmb-2019-0199

Table 3.  . Pooled treatment-emergent adverse events in Phase III sarecycline studies.

TEAE safety population (≥2% in either group) SC1401 and SC1402 pooled, n (%)
  Sarecycline (n = 994) Placebo (n = 996)
Nasopharyngitis 28 (2.8) 23 (2.3)
Upper respiratory infection 16 (1.6) 16 (1.6)
Headache 28 (2.8) 38 (3.8)
Nausea 32 (3.2) 17 (1.7)
Vomiting 13 (1.3) 9 (0.9)
Urinary tract infection 3 (0.3) 11 (1.1)

TEAE: Treatment-emergent adverse events.

Data taken from [25].

HHS Vulnerability Disclosure